HSPH1 inhibition downregulates Bcl-6 and c-Myc and hampers the growth of human aggressive B-cell non-Hodgkin lymphoma
- 12 March 2015
- journal article
- Published by American Society of Hematology in Blood
- Vol. 125 (11) , 1768-1771
Abstract
We have shown that human B-cell non-Hodgkin lymphomas (B-NHLs) express heat shock protein (HSP)H1/105 in function of their aggressiveness. Here, we now clarify its role as a functional B-NHL target by testing the hypothesis that it promotes the stabilization of key lymphoma oncoproteins. HSPH1 silencing in 4 models of aggressive B-NHLs was paralleled by Bcl-6 and c-Myc downregulation. In vitro and in vivo analysis of HSPH1-silenced Namalwa cells showed that this effect was associated with a significant growth delay and the loss of tumorigenicity when 104 cells were injected into mice. Interestingly, we found that HSPH1 physically interacts with c-Myc and Bcl-6 in both Namalwa cells and primary aggressive B-NHLs. Accordingly, expression of HSPH1 and either c-Myc or Bcl-6 positively correlated in these diseases. Our study indicates that HSPH1 concurrently favors the expression of 2 key lymphoma oncoproteins, thus confirming its candidacy as a valuable therapeutic target of aggressive B-NHLs. Key Points In human aggressive B-NHLs, HSPH1 favors c-Myc and Bcl-6 expression, and its inhibition provides significant antilymphoma activity. HSPH1 is expressed in function of Bcl-6 and c-Myc and constitutes a valuable alternative lymphoma therapeutic target of aggressive B-NHLs.Keywords
This publication has 23 references indexed in Scilit:
- Heat shock protein 70 regulates Tcl1 expression in leukemia and lymphomasBlood, 2013
- Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic targetBlood, 2011
- A Critical Role for GRP78/BiP in the Tumor Microenvironment for Neovascularization during Tumor Growth and MetastasisCancer Research, 2011
- Hsp90 as a Gatekeeper of Tumor Angiogenesis: Clinical Promise and Potential PitfallsJournal of Oncology, 2010
- A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6–dependent B cell lymphomasNature Medicine, 2009
- Principles of Cancer Therapy: Oncogene and Non-oncogene AddictionCell, 2009
- B-cell lymphoma 6 and the molecular pathogenesis of diffuse large B-cell lymphomaCurrent Opinion in Hematology, 2008
- Different localization of Hsp105 family proteins in mammalian cellsExperimental Cell Research, 2007
- Hsp105 family proteins suppress staurosporine-induced apoptosis by inhibiting the translocation of Bax to mitochondria in HeLa cellsExperimental Cell Research, 2006
- Viral Myc Oncoproteins in Infected Fibroblasts Down-modulate Thrombospondin-1, a Possible Tumor Suppressor GeneJournal of Biological Chemistry, 1996